Holodniy, Mark, Kaiser, Jon D · Journal of psychiatric research · 2019 · DOI
Researchers tested a combination treatment called KPAX002—containing a stimulant medication (methylphenidate) plus vitamins and nutrients meant to support energy production in cells—in 17 people with Gulf War Illness. After 12 weeks, patients reported about 25% improvement in their overall symptoms, including better fatigue, brain fog, sleep, and pain. The treatment was generally safe and well-tolerated, though a larger, more rigorous study is needed to confirm these results.
While Gulf War Illness and ME/CFS are distinct conditions, both involve fatigue, cognitive impairment, sleep dysfunction, and potential mitochondrial metabolic abnormalities. This trial provides preliminary evidence that combined pharmacological and micronutrient support targeting cellular energy metabolism may benefit symptom severity, potentially informing future therapeutic approaches for post-exertional malaise and energy-related disorders. Replication in larger, placebo-controlled trials is essential before clinical recommendations can be made.
This open-label study does not prove KPAX002 is effective—without a placebo control group, observed improvements may reflect placebo effect, natural disease fluctuation, or subject expectation bias. The small sample size (n=15 ITT) limits generalizability, and completion by only 10 subjects increases risk of dropout bias. This study cannot establish whether methylphenidate or the micronutrient formula is responsible for any benefit, nor whether benefits would persist beyond 12 weeks.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →